Results 141 to 150 of about 27,341 (230)

High cholesterol absorption efficiency enhances proatherogenic properties of low‐density lipoprotein particles

Journal of Internal Medicine, Volume 299, Issue 6, Page 711-725, June 2026.
Abstract Background and Aims High cholesterol absorption efficiency is determined by genetic variation in small intestinal sterol transporters and affects one‐third of individuals. Their risk for atherosclerotic cardiovascular disease (ASCVD) is increased compared with low cholesterol absorbers, despite similar serum lipid concentrations.
Katariina Öörni, Lauri Äikäs, Maija Ruuth, Feven Tigistu‐Sahle, Reijo Käkelä, Ingmar Wester, Helena Gylling, Piia Simonen   +7 more
wiley   +1 more source

Poor long‐term cardiovascular risk factor management after acute coronary syndrome: An observational cohort study

Journal of Internal Medicine, Volume 299, Issue 6, Page 726-740, June 2026.
Abstract Background Cardiovascular risk factor control reduces the risk of recurrent events after acute coronary syndrome (ACS). Long‐term post‐ACS management is poorly studied. Objectives To assess frequency of low‐density lipoprotein cholesterol (LDL‐C) and systolic blood pressure (SBP) monitoring and target achievement during 3 years post‐ACS ...
Jessica Schubert, Maria K. Svensson, Margret Leosdottir, Bertil Lindahl, Håkan Melhus, Elin Täufer Cederlöf, Nina Johnston, Thomas Cars, Emil Hagström   +8 more
wiley   +1 more source

Effect of ezetimibe on cholesterol transit in mice.

, 2016
A, An illustrated protocol for the 3H-cholesterol distribution assay. B, Upper; 3H-decay per minute (DPM) count distribution 3 h after 3H-cholesterol was given orally to C57BL/6J mice.
Hiraku Ono (3214602), Yasuhiro Takenaka (423921), Shigehiro Katayama (423926), Takuya Awata (423925), Ikuo Inoue (423922), Takayuki Murakoshi (3214605), Takanari Nakano (423923)   +6 more
core   +1 more source

Solubility Enhancement of Ezetimibe by a Cocrystal Engineering Technique

, 2016
The present study illustrates the formation and characterization of three different cocrystals of ezetimibe using methyl paraben as a coformer, employing three different processes, namely, solution crystallization, liquid assisted grinding, and reaction ...
Kumari Sugandha (1755535), Samrat Mukherjee (1628734), Jinu Isaac (1755538), Santanu Kaity (1755532), Animesh Ghosh (1571146)   +4 more
core   +1 more source

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis

Annals of Medicine
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain ...
Areej S. Albawa’neh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Amal Albawaana, Gamila Ahmed, Rami H. Al-Rifai, Bassam R. Ali   +6 more
doaj   +1 more source

Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes [PDF]

, 2011
Ezetimibe selectively inhibits dietary and biliary cholesterol absorption and reduces serum cholesterol levels when administered alone (monotherapy) and along with common lipid-regulating agents (combination therapy).
キシモト, ミヤコ, Osame, Keiichiro, スギヤマ, タケヒロ, オサメ, ケイイチロウ, タカラベ, ダイスケ, Sugiyama, Takehiro, Takarabe, Daisuke, オカモト, マサヒデ, Okamoto, Masahide, ノダ, ミツヒコ, Kishimoto, Miyako, Noda, Mitsuhiko   +11 more
core  

Ezetimibe-associated adverse effects: what the clinician needs to know

, 2008
OBJECTIVE: Ezetimibe is a relatively new lipid lowering agent, which is indicated for the treatment of primary hypercholesterolaemia, either as monotherapy or in combination with other hypolipidaemic drugs.
Elisaf, M. S., Liberopoulos, E. N., Florentin, M.   +2 more
core  

Ezetimibe Increases Endogenous Cholesterol Excretion in Humans

, 2017
Objective— Ezetimibe improves cardiovascular outcomes when added to optimum statin treatment. It lowers low-density lipoprotein cholesterol and percent intestinal cholesterol absorption, but the exact cardioprotective mechanism ...
Xiaobo Lin, Lina Ma, Richard E. Ostlund, Michael Wallendorf, Susan B. Racette   +4 more
core   +1 more source

Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial

Lipids in Health and Disease
Objective Rosuvastatin plus ezetimibe improves the lipid-lowering effect through different mechanisms of action. This study intended to compare the efficacy and safety of the fixed-dose combination (FDC) of rosuvastatin/ezetimibe vs.
Xianyou Ji, Jinlan Xia, Hong Zhang, Changjie Ren, Guang Ma, Shenwen Fu, Jun Zhang, Ying Chen, Xuebin Han, Jianming Zhang, Zhengxu Fang, Bo Yang, Baisong Yang, Wenjun Huang, Gang Yin, Hong Qi, Hao Gong, Dongfang Wang, Liuyi Hao, Xiufeng Zhao, Zhaohui Pei, Peijian Wang, Xiaodong Li, Ling Lin, De Li, Zhi Li, Lin Zhang, Bo Yin, Ying Cheng, Zhiqing You, Jianlong Sheng, Jie Wu, Ling Chen, Zhongcai Fan, Wang Zhao, Shuiping Zhao   +35 more
doaj   +1 more source

Introduction Ezetimibe: efficacy and safety in clinical trials

, 2002
The lipid-modifying efficacy and safety of once-daily ezetimibe 10 mg have been established in phase III clinical trials, in which ezetimibe has been investigated as monotherapy, as an add-on to ongoing statin therapy, and as combination therapy with ...
C M Ballantyne, MD Christie Ballantyne
core